Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company Drug

UTC Therapeutics Gains FDA Clearance for CAR-T Therapy UCLM805 in MSLN-Positive Solid Tumors

Fineline Cube Aug 4, 2025

China-based cell therapy biotech UTC Therapeutics announced receiving clearance from the US Food and Drug...

Company Drug Policy / Regulatory

FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) is implementing new safety measures for opioid pain...

Company Drug

Luye Pharma’s LY03021 Completes Enrollment of First Healthy Subject in Phase I Trial

Fineline Cube Aug 4, 2025

China-based Luye Pharma Group (HKG: 2186) announced on August 3, 2025, that its self-developed Class...

Company Deals

AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis

Fineline Cube Aug 1, 2025

China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany’s Dr. Falk Pharma GmbH to...

Company Deals

Grand Pharma Partners with IRE EliT to Distribute 68Ge/68Ga Generators in China

Fineline Cube Aug 1, 2025

On July 31, 2025, China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced a strategic collaboration...

Company Drug

Lee’s Pharma’s Socazolimab Approved by NMPA for ES-SCLC First-Line Treatment

Fineline Cube Aug 1, 2025

Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced that its in-licensed programmed-death ligand 1 (PD-L1) monoclonal...

Company Deals

BrightGene and CR Sanjiu Collaborate on BGM0504 Injection Development and Commercialization

Fineline Cube Aug 1, 2025

China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166) and its affiliated companies announced a collaboration...

Company

AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth

Fineline Cube Aug 1, 2025

US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing...

Company

BMS Q2 Earnings Reflect Strategic Investments; Maintains Full-Year Revenue Growth Outlook

Fineline Cube Aug 1, 2025

US major Bristol-Myers Squibb (BMS; NYSE: BMY) reported Q2 2025 financial results, revealing total revenues...

Policy / Regulatory

China’s NHSA Issues Rules for Instant Settlement of Medical Insurance Funds

Fineline Cube Aug 1, 2025

China’s National Healthcare Security Administration (NHSA) has issued the “Interim Administrative Rules for Instant Settlement...

Company Deals

Hybio and BrightGene Partner on Peptide Raw Material Supply for Global Drug Commercialization

Fineline Cube Aug 1, 2025

China-based Hybio Pharmaceutical Co., Ltd. (SHE: 300199) and China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA:...

Company Drug

BeOne Medicines’ BGB-16673 Granted PRIME Designation by EMA for Waldenström’s Macroglobulinemia

Fineline Cube Aug 1, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced on July 31, 2025,...

Company Drug

Neurodawn’s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection

Fineline Cube Aug 1, 2025

China-based Neurodawn Pharmaceutical Co., Ltd.’s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan...

Policy / Regulatory

NMPA Seeks Public Feedback on Draft Regulations for Internet Drug and Medical Device Information Services

Fineline Cube Aug 1, 2025

On July 31, 2025, China’s National Medical Products Administration (NMPA) commenced soliciting public comments on...

Company Drug

Haisco’s Ciprofol NDA Accepted by FDA: A Milestone for Chinese Anesthesia Innovation

Fineline Cube Aug 1, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that the New Drug Application (NDA)...

Company Drug

AstraZeneca’s Ultomiris Gains NMPA Approval for Neuromyelitis Optica Spectrum Disorder

Fineline Cube Aug 1, 2025

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Chipscreen’s Next-Gen Brain-Penetrant Aurora B Inhibitor CS231295 Gains FDA Clearance for Advanced Solid Tumors

Fineline Cube Aug 1, 2025

On July 31, 2025, the investigational new drug (IND) application for Shenzhen Chipscreen Biosciences Co.,...

Company Drug

Hengrui Receives Clinical Clearance for HRS-5041 in Prostate Cancer Treatment

Fineline Cube Aug 1, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance from...

Company Deals

Porton Advanced and Cellstore Partner to Optimize Cell Therapy Drug Cryopreservation

Fineline Cube Jul 31, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. and Cellstore announced today...

Company Deals

ImmuneOnco Receives $10M Milestone Payment from Instil Bio for IMM2510/IMM27M Collaboration

Fineline Cube Jul 31, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced today that it has received a...

Posts pagination

1 … 168 169 170 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.